Merck & Company (MRK-N) Stock Predictions - Stockchase
WATCH LIST
174
Merck & Company (MRK-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Merck & Company

MRK-N

32 watching          
Join the Discussion

Merck & Company (MRK-N) SAVE Apr, 24, 2019, 4:05 pm

74.72 0.12 (0.16%)

About Merck & Company (MRK-N)

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. More at Wikipedia

What the experts are saying about MRK-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Merck & Company(MRK-N) 

March 22, 2019

(A Top Pick Apr 30/18, Up 44%) Likes healthcare. Chart is up and to the right. Any volatility has tended to be about politics. Secular bull market. Healthcare should be a core holding, and Merck would be a good place to start. Surgical devices like Baxter are also good.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Apr 30/18, Up 44%) Likes healthcare. Chart is up and to the right. Any volatility has tended to be about politics. Secular bull market. Healthcare should be a core holding, and Merck would be a good place to start. Surgical devices like Baxter are also good.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$82.290
Owned Owned
No

DON'T BUY
Merck & Company(MRK-N) 

February 6, 2019

Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$77.440
Owned Owned
No

PAST TOP PICK
Merck & Company(MRK-N) 

December 3, 2018

(A Top Pick Jul 05/18, Up 29%) An investor should diversify in the health sector, and MRK is a diversified health company. MRK has done very well in their oncology side. They're becoming dominant in immunotherapies. MRK gets their science and data right, unlike their peers.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jul 05/18, Up 29%) An investor should diversify in the health sector, and MRK is a diversified health company. MRK has done very well in their oncology side. They're becoming dominant in immunotherapies. MRK gets their science and data right, unlike their peers.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$79.220
Owned Owned
Yes

TOP PICK
Merck & Company(MRK-N) 

December 3, 2018

A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$79.220
Owned Owned
Yes

HOLD
Merck & Company(MRK-N) 

September 12, 2018

The small and mid-cap pharma sector has been on fire he says.  On a relative basis, he believes, this may lead to acquisitions by the larger players.  MRK-N has a big war chest to do this.  He has not entered this space yet, but it is starting to check all his boxes for entry.  He would suggest an ETF to diversify risk, especially at this stage of the cycle.    

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The small and mid-cap pharma sector has been on fire he says.  On a relative basis, he believes, this may lead to acquisitions by the larger players.  MRK-N has a big war chest to do this.  He has not entered this space yet, but it is starting to check all his boxes for entry.  He would suggest an ETF to diversify risk, especially at this stage of the cycle.    

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$69.860
Owned Owned
No

TOP PICK
Merck & Company(MRK-N) 

July 13, 2018

He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$62.890
Owned Owned
Yes

PAST TOP PICK
Merck & Company(MRK-N) 

July 5, 2018

(A Top Pick September 14/17 - Down 4%) Nothing has changed. Still good dividends and fundamentals. Solid holding.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick September 14/17 - Down 4%) Nothing has changed. Still good dividends and fundamentals. Solid holding.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$61.640
Owned Owned
Yes

TOP PICK
Merck & Company(MRK-N) 

July 5, 2018

Like the stability. They are one of the leaders in immunotherapy and other lines of business.  Core holding. Dividend yield is 3.1%. Market cap $165.8 billion. (Analysts’ price target is $69.16)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Like the stability. They are one of the leaders in immunotherapy and other lines of business.  Core holding. Dividend yield is 3.1%. Market cap $165.8 billion. (Analysts’ price target is $69.16)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$61.640
Owned Owned
Yes

BUY
Merck & Company(MRK-N) 

June 26, 2018

What healthcare stock to buy? In Canada, he likes Chartwell, in the U.S, Merck (MRK-N), and in Europe, Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

What healthcare stock to buy? In Canada, he likes Chartwell, in the U.S, Merck (MRK-N), and in Europe, Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Campbell

President, Campbell and Lee Inv...

Price Price
$60.720
Owned Owned
Unknown

TOP PICK
Merck & Company(MRK-N) 

April 30, 2018

He thinks the worst of the drugs going off patent is over.  These guys have been really hurt by their patent cliff.  It is a really good value name.  He sees resistance at $67.  It is a good sector to be in.  (Analysts’ target: $68.79).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He thinks the worst of the drugs going off patent is over.  These guys have been really hurt by their patent cliff.  It is a really good value name.  He sees resistance at $67.  It is a good sector to be in.  (Analysts’ target: $68.79).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$58.870
Owned Owned
Yes

DON'T BUY
Merck & Company(MRK-N) 

April 5, 2018

It is a stable stock with stable earnings.  But the price momentum is weak.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It is a stable stock with stable earnings.  But the price momentum is weak.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Mann

CIO & Co-F, Edgehill Patners...

Price Price
$54.530
Owned Owned
No

TOP PICK
Merck & Company(MRK-N) 

March 21, 2018

A large, diversified pharma company with a hepatitis C franchise, but are really into immonotherapy and chemotherapy. They are getting positive results with their drugs, and will be the leader in this space. Own this with BMY-N and AZN-N preferrably (and not alone). A must-own stock in healthcare given their pipeline and leadership. Dividend yield of 3.5%. (Analysts' target of $67.25) 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A large, diversified pharma company with a hepatitis C franchise, but are really into immonotherapy and chemotherapy. They are getting positive results with their drugs, and will be the leader in this space. Own this with BMY-N and AZN-N preferrably (and not alone). A must-own stock in healthcare given their pipeline and leadership. Dividend yield of 3.5%. (Analysts' target of $67.25) 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$54.690
Owned Owned
Yes

COMMENT
Merck & Company(MRK-N) 

November 7, 2017

Unfortunately, pharmas/biotech have had a bit of a rough go. It was the mega-caps, not the small guys. This one reason he likes using ETF's in his mix. He prefers using the Spider S&P Biotech ETF (XBI-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Unfortunately, pharmas/biotech have had a bit of a rough go. It was the mega-caps, not the small guys. This one reason he likes using ETF's in his mix. He prefers using the Spider S&P Biotech ETF (XBI-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$55.590
Owned Owned
No

TOP PICK
Merck & Company(MRK-N) 

September 14, 2017

He likes their leadership in drug therapies.  They have their HEP-C and diabetes franchises.  It is an easy hold for him.  They are well diversified.  They are number 3 in animal health products.  It has a PE of 15.5 times next year’s earnings.  (Analysts’ target: $70.00).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes their leadership in drug therapies.  They have their HEP-C and diabetes franchises.  It is an easy hold for him.  They are well diversified.  They are number 3 in animal health products.  It has a PE of 15.5 times next year’s earnings.  (Analysts’ target: $70.00).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$66.120
Owned Owned
Yes

PAST TOP PICK
Merck & Company(MRK-N) 

September 14, 2017

(Top Pick Feb 22/17, Up 3%)  It has traded in line with others.  It is a wonderfully run company with a deep pipeline into diabetes and arthritis.  They are in the forefront of immunotherapies for arthritis.  They are the leaders.  15.5 times forward earnings.  It should trade in a double digit PE.  He likes it for leadership and diversification. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Top Pick Feb 22/17, Up 3%)  It has traded in line with others.  It is a wonderfully run company with a deep pipeline into diabetes and arthritis.  They are in the forefront of immunotherapies for arthritis.  They are the leaders.  15.5 times forward earnings.  It should trade in a double digit PE.  He likes it for leadership and diversification. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$66.120
Owned Owned
Yes

Showing 1 to 15 of 174 entries
Successfully Saved Company
Successfully Saved Company